Schedule One - Roquefort Therapeutics PLC
Roquefort Therapeutics plc (AIM: ROQ) has announced a significant restructuring and capital raise as it prepares for its readmission to AIM on March 27, 2026, under the new name Coiled Therapeutics plc. The company will acquire the AO-252 Licence from A2A Pharmaceuticals for approximately £31.90 million, which will be satisfied through the issuance of shares. In conjunction with this acquisition, Roquefort plans to raise £8.5 million at a price of 10 pence per share, leading to an anticipated market capitalisation of £42.6 million upon readmission. The AO-252 molecule, a novel inhibitor targeting TACC3 protein-protein interactions, has demonstrated promising preclinical efficacy in various cancers and is currently undergoing a Phase I trial in the United States, with initial results indicating a benign safety profile.
Historically, Roquefort has focused on developing next-generation medicines for hard-to-treat cancers since its establishment in 2020. The acquisition of the AO-252 Licence marks a strategic pivot as the company shifts its primary operations to the United States, a move that aligns with its ambition to enhance its clinical development capabilities and market reach. The AO-252 molecule has shown strong preclinical efficacy, including complete tumour regression in several cancer types, which positions Roquefort to potentially capture significant market interest, particularly in the oncology sector where innovative therapies are in high demand.
Financially, Roquefort's current market capitalisation is projected to be £42.6 million post-readmission, with the company raising £8.5 million to support its operations and clinical trials. The funding will be critical as the company navigates the costs associated with the ongoing Phase I trial of AO-252, which is crucial for advancing to later-stage clinical trials. However, the reliance on share issuance to fund the acquisition raises concerns about potential dilution for existing shareholders, particularly given that approximately 49.3% of the AIM securities will not be in public hands after the readmission. The company’s cash balance and burn rate have not been disclosed, making it challenging to assess the exact funding runway; however, the capital raised should provide a cushion for operational expenses in the near term.
In terms of valuation, Roquefort's anticipated market capitalisation of £42.6 million places it in a competitive position within the biotech sector. However, direct peer comparisons are limited due to the unique focus on oncology and the specific stage of development. For instance, companies like AIM: MGC Pharmaceuticals and AIM: Avacta Group, which are also engaged in oncology and therapeutics, provide some context. MGC Pharmaceuticals has a market cap of approximately £30 million and is focused on cannabinoid-based therapies, while Avacta Group, with a market cap of around £100 million, is developing cancer therapies and diagnostics. Roquefort's valuation at £42.6 million suggests a premium compared to MGC Pharmaceuticals, which is indicative of the market's optimism regarding the AO-252 molecule's potential.
Execution risk remains a significant concern for Roquefort, particularly given the ambitious timeline for the Phase I trial of AO-252. The company must demonstrate not only the efficacy and safety of the drug but also navigate the complexities of regulatory approvals in the United States. The shift in operational focus to the U.S. market introduces additional jurisdictional risks, including the need to comply with stringent FDA regulations. Furthermore, the reliance on a single product, AO-252, for future growth could pose a risk if the trial results do not meet expectations or if unforeseen challenges arise during clinical development.
Looking ahead, the next measurable catalyst for Roquefort will be the results from the ongoing Phase I trial of AO-252, with updates expected in the coming months. The success of this trial will be pivotal in determining the company's trajectory and its ability to secure further funding for subsequent phases of development. The anticipated readmission to AIM and the strategic acquisition of the AO-252 Licence represent a crucial juncture for Roquefort, as it seeks to establish itself as a key player in the oncology therapeutics space.
In conclusion, the announcement regarding Roquefort Therapeutics' acquisition of the AO-252 Licence and the associated capital raise is classified as significant. The strategic shift to the U.S. market and the focus on a promising oncology candidate could enhance the company's valuation and market position. However, the reliance on share issuance raises dilution concerns, and the execution risks associated with clinical trials remain a critical factor for investors. Overall, while the potential for value creation exists, the path forward will require careful navigation of regulatory hurdles and clinical development challenges.